Novo Nordisk's Wegovy sales in US still rising – albeit at slower pace
Obesity drug Wegovy’s sales development in the US is positive, a bank assesses, as the Danish drugmaker’s prescription numbers for a number of products continue their upward trend.
By marketwire, translated by katrine gøthler
Novo Nordisk’s obesity drug, Wegovy (semaglutide), continued its upward journey on the US market in the year’s seventh week, although at a bit slower pace. This follows the treatments relaunch in all doses around the turn of the year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk stock sets closing price record
For subscribers
Analyst: Wegovy prescriptions keep pace in week 4
For subscribers
